However, together with the two cases with chromosomal translocations involving the NKX2-3 locus, increased NKX2-3 expression was detected in 12 of 393 samples from patients with untreated B-cell lymphoid malignancies (3%), mainly including 6 of 82 (7%) SMZLs and 4 of 67 (6%) mucosa-associated lymphoid tissue (MALT) lymphomas. This evidence concerns the gene NKX2-3 and MALT lymphoma.